In summary, the results presented here are the first to address the potential therapeutic role of XAC 1396-11, an SMI of XIAP for NSCLC, and the possibility for synergy with cytotoxics commonly used in the treatment of the disease. This evidence concerns the gene XIAP and non-small cell lung carcinoma.